Actinium Pharmaceuticals (ATNM)

• Market cap: $45.5M
• 1 day: -3.95%
• 5 days: 5.04%
• 1 month: 10.61%
• 3 months: 26.96%
• 6 months: -11.52%
• Year to date: 15.87%
• 1 year: -85.24%
• 5 years: -72.91%
• 10 years: -98.06%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Employees: 37

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,417% more call options, than puts

Call options by funds: $91K | Put options by funds: $6K

93% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 14

1.09% less ownership

Funds ownership: 27.16% [Q3] → 26.07% (-1.09%) [Q4]

4% less funds holding

Funds holding: 72 [Q3] → 69 (-3) [Q4]

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

36% less capital invested

Capital invested by funds: $15.9M [Q3] → $10.2M (-$5.65M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 174% upside
• Avg. target: $4 174% upside
• High target: $4 174% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 81 / 389 met price target

174% upside $4

Buy Reiterated

12 May 2025